Inhibitors of the anaplastic lymphoma kinase (Q28267124)

https://api.crossref.org/works/10.1517/13543784.2012.690031

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

ALK rearrangement in sickle cell trait‐associated renal medullary carcinoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Activating mutations in ALK provide a therapeutic target in neuroblastoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Identification of ALK as a major familial neuroblastoma predisposition gene

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

The genomic landscapes of human breast and colorectal cancers

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Somatic mutations affect key pathways in lung adenocarcinoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Integrated genomic analyses of ovarian carcinoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Crizotinib in Anaplastic Large-Cell Lymphoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.2012.690031

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

The anaplastic lymphoma kinase in the pathogenesis of cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Inflammatory myofibroblastic tumours: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Pulmonary Inflammatory Myofibroblastic Tumor Expressing a Novel Fusion, PPFIBP1–ALK: Reappraisal of Anti-ALK Immunohistochemistry as a Tool for Novel ALK Fusion Identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

RET, ROS1 and ALK fusions in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Oncogenic mutations of ALK kinase in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Exome sequencing identifies GRIN2A as frequently mutated in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Biological role of anaplastic lymphoma kinase in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

CD30-targeted antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Through the "gatekeeper door": exploiting the active kinase conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031

Abstract A42: ALK and cMET expression in glioblastoma multiforme: Implications for therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690031